Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.58 |
| ▸ | CCR8 | P51685 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386644 | 0.80 | CCR1 (0.70) | CCR1CCR5CCR8DYRK1ACLK4 | |
| SCHEMBL12753751 | 0.80 | CCR1 (0.70) | CCR1CCR5CCR8DYRK1ACLK4 | |
| SCHEMBL4555939 | 0.79 | CYP2A6 (0.56) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL16471822 | 0.78 | CCR1 (0.68) | CCR1CCR5CCR8DYRK1ACLK4 | |
| SCHEMBL3759998 | 0.76 | DYRK1A (0.56) | CCR1CCR5CCR8DYRK1ACLK4 | |
| SCHEMBL28590584 | 0.76 | ASIC3 (0.44) | PLAUCYP19A1TGFBR1CYP1A2CYP3A4 | |
| SCHEMBL182529 | 0.75 | CCR1 (1.00) | CCR1CCR5CCR8DYRK1ACLK4 | |
| SCHEMBL29395249 | 0.75 | CCR1 (1.00) | CCR1CCR5CCR8DYRK1ACLK4 | |
| SCHEMBL27729200 | 0.75 | KIF11 (0.39) | CYP2A6 | |
| SCHEMBL361043 | 0.75 | CYP3A4 (0.52) | DYRK1ACLK4CYP1A1CYP1A2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | claimed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | CCR1 3931/4885CCR5 1200/4885CCR8 2580/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | CCR1 4371/4885CCR5 1219/4885CCR8 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.